Evaluation of optimized injection dose and acquisition time using body mass index for three-dimensional whole-body FDG-PET

OBJECTIVE: The standardized uptake value (SUV) is a relative measure of tracer uptake in tissue used in (18)F-FDG PET. However, the quality of ordered subset expectation maximization (OS-EM) images is sensitive to the number of iterations, because a large number of iterations leads to images with checkerboard noise. The main advantage of data acquisition in the three-dimensional (3D) mode is the high sensitivity to better exploit the intrinsic spatial resolution and the lower injection dose given to patients. In the 3D mode, the scatter fraction is higher, and, for a given administered dose, the random fraction is higher than that in the two-dimensional mode, which implies that correction methods need to be more accurate. Moreover, in clinical oncology (18)F-FDG PET studies, patients have a wide variety of body shapes and sizes, which may impact image statistics. Consequently, it is necessary to make constant the acquisition (true) counts. The purpose of this study was to optimize injection dose and acquisition time in consideration of body mass index (BMI) for 3D whole-body (18)F-FDG PET. METHODS: A dedicated PET scanner, SIEMENS ECAT EXACT HR(+), was used to scan images of clinical data. The injection dose for BMI of <14-19, 19-22, 22-25, and 25< (kg/m(2)) were, 92.5 MBq, 111.0 MBq, 129.5 MBq, and 148.0 MBq, respectively. The emission scan time per bed position for BMI of <14-19, 19-22, 22-25, and >25 (kg/m(2)) were, 120, 120, 180, and 240 sec, respectively. A total of 20 patient subjects were evaluated as to true counts per bin (T/bin) of sinogram data and measured activity concentrations for the region of interest in the liver section. RESULTS: T/bin was stable using an optimized protocol that took into consideration the BMI for any type of body morphology. The overall coefficient of variation was 7.27% for radioactivity concentration. Additionally, Gaussian filtering (8 mm FWHM) after reconstruction by the OS-EM method provided stable SUV values even when the iteration number was increased 30 times over. CONCLUSION: Optimization of injection dose and acquisition time indicated that BMI was a clinically useful acquisition protocol for 3D whole-body (18)F-FDG PET.     

Evaluation of noise equivalent count parameters as indicators of adult whole-body FDG-PET image quality

Objectives

The aim of this study was to assess variation of qualitative and quantitative PET/CT image quality parameters with acquisition time, injection activity and body mass for a representative group of adults undergoing whole-body PET/CT imaging.

Methods

PET scan data from sixty patients were reconstructed with a scan time of 1, 2 and 3 min/bed position. These images were visually scored and three quantitative parameters were calculated: noise equivalent counts per axial length (NEC_patient), noise equivalent count density (NEC_density) and liver signal to noise ratio (liver SNR). The ability of the three quantitative parameters to discriminate qualitative image quality was assessed using ROC analysis.

Results

The quantitative parameters were shown to discriminate images of good/excellent quality from those of poorer image quality with a high degree of accuracy (ROC area >0.9); further, NEC_patient had significantly higher discrimination than either NEC_density or liver SNR (ROC area = 0.97).

Conclusions

NEC_patient, NEC_density and liver SNR all have high discrimination for qualitatively assessed PET image quality. NEC_patient in particular is an effective objective indicator of patient image quality, which will help to assess and standardise scan protocols for purposes such as multi-centre research trials.     

Advantage of delayed whole-body FDG-PET imaging for tumour detection

Delayed imaging that coincides with the highest uptake of fluorine-18 fluorodeoxyglucose (FDG) by tumour may be advantageous in oncological positron emission tomography (PET), where delineation of metastasis from normal tissue background is important. In order to identify the better imaging protocol for tumour detection, whole-body FDG-PET images acquired at 1 h and 2 h after injection were evaluated in 22 subjects, with a post-injection transmission scan at 90 min for attenuation correction. After visual interpretation, tumour uptake [tumour standardised uptake ratio (SUR)], normal tissue uptake (normal SUR) and tumour to background contrast (tumour SUR/normal tissue SUR) were evaluated in the images acquired at 1 h and at 2 h. Most malignant lesions, including primary lung cancer, metastatic mediastinal lymph nodes and lymphoma lesions, showed higher FDG uptake at 2 h than at 1 h. By contrast, benign lesions, with the exception of sarcoidosis, showed lower uptake of FDG at 2 h than at 1 h. Among normal tissues, the kidney, liver, mediastinum, lung, upper abdomen and left abdomen showed significant falls in FDG uptake from 1 h to 2 h. The lower abdomen, right abdomen and muscles (shoulder and thigh) showed no significant changes. Consequently, malignant lesions of the lung, mediastinum and upper abdomen showed significant increases in tumour to background contrast from 1 to 2 h. Three lesions (two lung cancers and a malignant lymphoma) that were equivocal on 1-h images became evident on 2-h images, changing the results of interpretation. All other malignant lesions were detected on 1-h images, but were clearer, with higher contrast, on 2-h images. Lesion-based sensitivity was improved from 92% (49/53) to 98% (52/53), and patient-based sensitivity from 78% (14/18) to 94% (17/18). It is concluded that delayed whole-body FDG-PET imaging is a better and more reliable imaging protocol for tumour detection.     

Advantage of delayed whole-body FDG-PET imaging for tumour detection.

Delayed imaging that coincides with the highest uptake of fluorine-18 fluorodeoxyglucose (FDG) by tumour may be advantageous in oncological positron emission tomography (PET), where delineation of metastasis from normal tissue background is important. In order to identify the better imaging protocol for tumour detection, whole-body FDG-PET images acquired at 1 h and 2 h after injection were evaluated in 22 subjects, with a post-injection transmission scan at 90 min for attenuation correction. After visual interpretation, tumour uptake [tumour standardised uptake ratio (SUR)], normal tissue uptake (normal SUR) and tumour to background contrast (tumour SUR/normal tissue SUR) were evaluated in the images acquired at 1 h and at 2 h. Most malignant lesions, including primary lung cancer, metastatic mediastinal lymph nodes and lymphoma lesions, showed higher FDG uptake at 2 h than at 1 h. By contrast, benign lesions, with the exception of sarcoidosis, showed lower uptake of FDG at 2 h than at 1 h. Among normal tissues, the kidney, liver, mediastinum, lung, upper abdomen and left abdomen showed significant falls in FDG uptake from 1 h to 2 h. The lower abdomen, right abdomen and muscles (shoulder and thigh) showed no significant changes. Consequently, malignant lesions of the lung, mediastinum and upper abdomen showed significant increases in tumour to background contrast from 1 to 2 h. Three lesions (two lung cancers and a malignant lymphoma) that were equivocal on 1-h images became evident on 2-h images, changing the results of interpretation. All other malignant lesions were detected on 1-h images, but were clearer, with higher contrast, on 2-h images. Lesion-based sensitivity was improved from 92% (49/53) to 98% (52/53), and patient-based sensitivity from 78% (14/18) to 94% (17/18). It is concluded that delayed whole-body FDG-PET imaging is a better and more reliable imaging protocol for tumour detection.     

Visualization of normal organs in whole-body FDG-PET imaging

It is important to know FDG accumulation in the normal distributions for interpreting whole-body PET imaging for tumor detection. Twenty-eight normal subjects were studied with whole-body PET imaging and were examined the intensity of FDG uptake in major organs and the factors which caused it's variety. Emission images were acquired and images were reconstructed without attenuation correction. The intensity of FDG uptake was classified into 4 grades visually. No accumulation was found in the thyroid, the esophagus and the spleen. The oral cavity, the liver, the stomach, and the colon were visualized in all subjects. The laryngeal muscle, the cervical muscle, and the heart accumulated FDG with various grade from 1 to 4 grades. No association was found between the intensity of uptake in the organs and volunteer's age. The fasting time was shorter in volunteers whose heart showed "high" grade than those showed less accumulation (p < 0.05). Serum concentration of free fatty acid was significantly lower in them, too (p < 0.05). Various FDG uptake was observed in many organs, especially the laryngeal muscle, the cervical muscle, and the heart. In our study, there was no facter which caused FDG uptake in organs except for the fasting time and the value of free fatty acid in the heart. Such analysis of whole-body FDG distributions in the normal subjects is valuable for tumor detection with FDG-PET.     

Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors

OBJECTIVE: Positron emission tomography (PET) using (18)F-fluoro-2-deoxy-D -glucose (FDG) has a limitation in detecting cerebral metastases; however, the feasibility of detection by inline PET/computed tomography (CT) system remains unknown. We evaluated the accuracy of FDG-PET/CT of body imaging protocol for the detection of cerebral metastases when compared with PET alone and CT alone. METHODS: Fifty patients underwent whole-body FDG-PET/CT scanning including the brain and contrast enhanced brain MR (magnetic resonance) scan. PET-only, CT-only, and the fused images were interpreted, and the confidence of presence of cerebral metastases was recorded using a five-point grading scale. Area under the receiver-operating characteristic (ROC) curve (Az) was calculated. Differences among the three modalities were tested with the Cochran-Q test, followed by multiple comparisons using the McNemar test with Bonferroni adjustment. RESULTS: Magnetic resonance imaging revealed 70 cerebral metastatic lesions in 20 patients. Patient-based analysis showed that the sensitivity, specificity, accuracy, and Az of PET-alone interpretation were 45%, 80%, 66%, and 0.6025, respectively, those of CT-alone interpretation were 50%, 97%, 78%, and 0.7158, respectively, and those of fused-image interpretation were 50%, 93%, 76%, and 0.7242, respectively. ROC analysis revealed significant differences among the three interpretation methods (P = 0.0238) and between PET and PET/CT (P = 0.0129). The sensitivity of PET, CT, and fused-image interpretation for detecting 70 lesions was 13%, 20%, and 20%, respectively. CONCLUSIONS: Even with an integrated PET/CT scanner of body imaging protocol, the sensitivity of cerebral metastases remained unsatisfactory. To assess intracranial lesions, MR scanning should still be considered.     

Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: A systematic review and meta-analysis

Background

A meta-analysis was conducted to evaluate the accuracy of whole-body positron emission tomography (PET) or PET/CT in M staging of nasopharyngeal carcinoma (NPC).

Methods

Through a search of relevant English language studies from October 1996 to September 2011, pooled estimated sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, and summary receiver operating characteristic (SROC) curves of whole-body PET or PET/CT in M staging of NPC were calculated.

Results

Three PET and 5 PET/CT studies were identified. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG-PET or PET/CT were 0.83 (95% confidence interval [CI], 0.77–0.88), 0.97 (95% CI, 0.95–0.98), 23.38 (95% CI, 16.22–33.69), and 0.19 (95% CI, 0.13–0.25), respectively. The area under curve was 0.9764 and Q* index estimate was 0.9307 for FDG-PET or PET/CT.

Conclusion

Current evidence confirms the good diagnostic performance of the whole-body FDG-PET or PET/CT in M staging of NPC.     

Impact of body habitus on quantitative and qualitative image quality in whole-body FDG-PET

Obtaining consistent high image quality is desirable for clinical positron emission tomography (PET). Body morphology may impact image quality. The purpose of this study was to define the average and the range of body sizes in patients undergoing tumor PET studies in our center and to determine how the body habitus affects the statistical and visual quality of PET images. Height, weight, body surface area (BSA), and body mass index (BMI) were determined in 101 male and 101 female patients (group 1) referred for clinical PET. The summed total counts from three consecutive transaxial slices on non-attenuation-corrected (NAC) 2D fluorine-18 fluorodeoxyglucose (FDG) PET images, which included the largest liver section and no lesions, were determined and compared with body morphology and injected doses (ID) in a representative group of 30 male and 30 female patients (group 2) spanning a range of body morphologies. The visual quality of images was also evaluated using a scoring system by three readers. The average height, weight, and BSA were greater in male than in female patients, but the average BMI was not different between them in group 1. The largest value of weight or BMI was more than four times the smallest value in female patients. The total true counts were best correlated with ID/weight (mCi/kg) in group 2 ( r=0.929, P<0.0001). Intermediate to high total counts (930,000 or more) corresponded to ID/weight of 0.22 or higher. The average visual score was positively correlated with the total counts (rho=0.63, P<0.0001) and with ID/weight (rho=0.68, P<0.0001) on NAC images. The image quality in 22 (84.6%) of 26 patients with intermediate to high total counts was adequate to good, whereas that in 21 (61.8%) of 34 patients with lower total counts was suboptimal. A wide variety of body morphologies was observed in patients referred for clinical FDG-PET tumor studies in our center. The total counts and average image visual score were negatively correlated with weight. Counts in heavy patients were as low as one-fourth those in light patients. Adjusting injected FDG dose in each patient on the basis of body weight may be more appropriate to achieve consistent PET image quality than giving a fixed injected FDG dose.     

The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions

Purpose The aim of this study was to evaluate retrospectively the efficacy of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) for autoimmune pancreatitis (AIP) and associated extrapancreatic autoimmune lesions. Methods Whole-body FDG-PET or PET/computed tomography (CT) findings were reviewed in six patients with AIP. The initial PET scans were performed 1 h and 2 h after FDG injection in all six patients. Follow-up PET scans were performed during or following steroid therapy in five patients and in one patient who did not have steroid therapy. Results The initial PET scans revealed intense FDG uptake by AIP in all six patients. The maximum standardized uptake value (SUVmax) increased in four patients and was stable in two patients. The intense uptake in the pancreas disappeared during or following steroid therapy in five patients and in one patient who showed spontaneous remission of AIP. Abnormal FDG uptake by extrapancreatic autoimmune diseases was observed in five of the six patients: sclerosing sialadenitis (n = 5), lymphadenopathy (n = 5), retroperitoneal fibrosis (n = 2), interstitial nephritis (n = 2) and sclerosing cholecystitis (n = 1). Abnormal FDG uptake disappeared in the salivary glands (n = 4), lymph nodes (n = 4), retroperitoneum (n = 2), kidneys (n = 1) and gallbladder (n = 1) during or following steroid therapy and remained in the salivary glands and lymph nodes of a spontaneous remission patient. Conclusion These results suggest that whole-body FDG-PET may be useful for detecting AIP and associated extrapancreatic autoimmune lesions and for monitoring their disease activity but that dual time point imaging may not be useful for differentiating malignancy from AIP.     

The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers

OBJECTIVE: The aim of this study is to clarify the clinical utility of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) in determining the TNM classification in patients with oral cancer. METHODS: Twenty-five consecutive patients (14 male and 11 female; age range, 40 yr to 86 yr) with oral cancer were included in this study. The diagnostic accuracy for detecting cervical lymph nodes was investigated by comparing the results of CT and/or MRI and physical findings. For the semi-quantitative analysis, the tumor standardized uptake value (SUV) and tumor to background SUV ratio (T/B ratio) were assessed in primary tumors and cervical lymph nodes. RESULTS: All primary lesions were visualized on FDG-PET images. Even though artifacts from dental materials near the lesion hampered the delineation of primary tumors on CT/MRI, the extent of primary tumors was accurately assessed by FDG-PET. The SUV and T/B ratio in the primary tumor classified in higher T grade (T3 and T4) was significantly higher than that in lower T grade (T1 and T2) (mean +/- SD of SUV; 8.32 +/- 2.99 vs. 5.15 +/- 3.77, p < 0.01, mean +/- SD of T/B ratio; 6.96 +/- 3.23 vs. 3.61 +/- 2.76, p < 0.01). The SUV and T/B ratio of metastatic lymph nodes were also significantly higher than those of normal lymph nodes (mean +/- SD of SUV; 3.39 +/- 1.69 vs. 1.55 +/- 0.57, p < 0.001, mean +/- SD of T/B ratio; 2.46 +/- 1.08 vs. 1.03 +/- 0.22, p < 0.001). Among these three methods, FDG-PET in conjunction with CT/MRI showed the highest accuracy of 92%, but there were no significant differences in diagnostic accuracy among the three methods. For the semi-quantitative analysis, a threshold SUV of 2.0 provided 100% sensitivity, 82% specificity, and 88% accuracy. Furthermore, a threshold T/B ratio of 1.5 provided 100% sensitivity, 100% specificity, and 100% accuracy. Regarding the detection of distant metastasis, there was one positive result in FDG-PET showing distant pulmonary metastasis. CONCLUSIONS: Whole-body FDG-PET is an effective and convenient diagnostic tool for the evaluation of tumor staging in patients with oral cancer. Tumor staging by whole-body FDG-PET may, in fact, supplement the conventional staging by means of CT/MRI and physical findings.     

The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening

OBJECTIVE: FDG-PET has been used for cancer screening, mainly in East-Asia, and cancers are found not infrequently. However, their stages have not been clarified. We examined the detection rates of various cancers using whole-body PET for the screening of cancers in asymptomatic individuals, focusing on their clinical and pathological stages. METHODS: Whole-body PET was obtained as a part of our cancer screening program among 3,426 healthy subjects. All subjects participated in a course of PET examination in conjunction with conventional examinations including a medical questionnaire, tumor markers, immunological fecal occult blood test, neck and abdominal ultrasonography and whole body computed tomography. A diagnosis and staging was obtained by an analysis of the pathological findings or by an analysis of the clinical follow-up data. RESULTS: Malignant tumors were discovered in 65 lesions found in 3,426 participants (1.90%). The PET findings were true-positive in 46 of the 65 cancer cases. The cancers were found in the following organs: the colon 14; thyroid gland 10; stomach 7; lung 5; liver 3; breast 2; and one each in the kidney, gallbladder, esophagus, pancreas and retroperitoneum. The stages were as follows: stage 0 5, stage I 17, stage II 10, stage III 7, and stage IV 6. One was an unknown primary. There were 19 false-negative findings (0.6%) on PET. Six cancers (0.18%) were missed in our screening program. CONCLUSIONS: PET imaging has the potential to detect a wide variety of cancers at potentially curative stages. Most PET-negative cancers are early stage cancers, and thus can be detected using other conventional examinations such as endoscopy.     

Detection of atherosclerosis: systemic imaging for systemic disease with whole-body three-dimensional MR angiography--initial experience

In 100 consecutive patients with peripheral vascular disease whole-body three-dimensional magnetic resonance (MR) angiography was performed by using the rolling table platform system with a 1.5-T MR unit and five three-dimensional MR angiographic data sets during 72 seconds (0.2 mol per kilogram of body weight of gadobenate dimeglumine). Apart from the proved peripheral vascular disease, additional clinically relevant disease was found in 33 segments in 25 patients as follows: renal arterial narrowing (n = 15), carotid arterial stenosis (n = 12), subclavian arterial stenosis (n = 2), and abdominal aortic aneurysms (n = 4). Confirmatory studies performed in 11 patients in this study revealed no false-positive or false-negative findings at examination.     

Diagnostic accuracy of bone metastases detection in cancer patients: Comparison between bone scintigraphy and whole-body FDG-PET

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has become widely available and an important oncological technique. To evaluate the influence of PET on detection of bone metastasis, we compared the diagnostic accuracy of PET and conventional bone scintigraphy (BS) in a variety of cancer patients. METHODS: Consecutive ninety-five patients with various cancers, who received both PET and BS within one month, were retrospectively analyzed. A whole-body PET (from face to upper thigh) and a standard whole body BS were performed and these images were interpreted by two experienced nuclear medicine physicians with and without patient information using monitor diagnosis. Each image interpretation was performed according to 8 separate areas (skull, vertebra, upper limbs, sternum and clavicles, scapula, ribs, pelvis, and lower limbs) using a 5-point-scale (0: definitely negative, 1: probably negative, 2: equivocal, 3: probably positive, 4: definitely positive for bone metastasis). RESULTS: Twenty-one of 95 patients (22.1%) with 43 of 760 areas (5.7%) of bone metastases were finally confirmed. In untreated patients, 12 of 14 bone metastasis positive patients were detected by PET, while 9 of 14 were detected by BS. Three cases showed true positive in PET and false negative in BS due to osteolytic type bone metastases. In untreated cases, PET with and without clinical information showed better sensitivity than BS in patient-based diagnosis. For the purpose of treatment effect evaluation, PET showed better results because of its ability in the evaluation of rapid response of tumor cells to chemotherapy. Out of 10 cases of multiple-area metastases, 9 cases included vertebrae. There was only one solitary lesion located outside of FOV of PET scan in the femur, but with clinical information that was no problem for PET diagnosis. CONCLUSION: Diagnostic accuracy of bone metastasis was comparable in PET and BS in the present study. In a usual clinical condition, limited FOV (from face to upper thigh) of PET scan may not be a major drawback in the detection of bone metastases because of the relatively low risk of solitary bone metastasis in skull bone and lower limbs.     

Optimization of scanning parameters for CT colonography

To determine the optimal collimation, pitch and reconstruction interval for CT colonography, 10 spherical polyps between 1 mm and 10 mm diameter and made of tissue equivalent material with a CT number of 40 Hounsfield units (HU) were placed in the colon of an anthropomorphic phantom. The phantom was scanned at slice thicknesses of 3 mm, 5 mm and 7 mm and pitches of 1.0, 1.3, 1.5, 1.7 and 2.0 on an IGE Hispeed advantage system. Images were reconstructed for each scanning parameter at the minimum intervals allowed along the z-axis. The optimum scanning protocol was assessed by measuring maximum contrast between the polyp and air, sensitivity for detection of each polyp along the z-axis, and relative radiation dose. In addition, images were reviewed separately by two radiologists who graded polyp conspicuity as: 0, not seen; 1, faintly seen; 2, well seen. It was found that varying the scanning parameters caused a marked alteration in the maximum contrast between each polyp and air. For example, for the 5 mm polyp, the range of contrasts from best to worst case was 910-490 HU. It was noted that with contrasts of less than 500 HU, polyps were only faintly seen. A slice thickness of 3 mm with a pitch of 2 offers optimal polyp conspicuity with a relatively low radiation dose, we conclude that scanning parameters can be optimized for threshold contrast, radiation dose and subjective conspicuity. We propose an optimal parameter of 3 mm slice thickness and pitch 2.     

Optimization of contrast timing for breath-hold three-dimensional MR angiography

The purpose of this study was to determine the influence of various factors (age, weight, breathing, saline flush) on the contrast kinetics of a test bolus injection for the purpose of calculating the scan delay for optimized contrast-enhanced three-dimensional MR angiography. Initially, the test bolus administration was optimized by evaluating the influence of breathing (breathing versus breath-hold) and the administration of a saline flush after the contrast injection (no flush versus flush) on the kinetics of a 4-ml Gd-DTPA test bolus injection in three healthy volunteers. Subsequently, in 33 patients referred for three-dimensional MR angiography of the renal arteries, test bolus kinetics were correlated to age, weight, and heart rate. In addition, the image quality of the three-dimensional MR angiograms was assessed on a four-point scale with regard to vessel visibility. The administration of a saline flush after the contrast injection significantly shortened the first appearance time (14 versus 16 seconds, P < .05), as well as the time to maximal signal intensity (SI) (6 versus 10 seconds, P < .05) and increased both maximum (67 versus 151 seconds, P < .05) and the SI slope (6.4 versus 20.5 seconds, P < .05). Breath-holding was shown to have no significant affect on the test bolus kinetics. No correlation was found between physiologic parameters and test bolus kinetics in the patient group. Image quality was graded as sufficient for diagnostic purposes in 32 of 33 patients. The contrast travel time from injection site to the vascular system under consideration cannot be predicted based on physiologic parameters. This time interval can be reliably and accurately determined by a test bolus injection of a small volume of contrast agent followed by a saline flush during normal breathing.     

Reduction of reconstruction time and data volume of sinogram by angular compression for clinical three-dimensional whole body FDG-PET

In positron emission tomography (PET), the large number of lines of responses in three-dimensional (3D) acquisition mode creates a high volume of sinogram data and increases reconstruction time in iterative reconstruction. We tried to decrease sinogram data volume by reducing the number of views using angular compression and then evaluated the accuracy of this mashed mode. Three methods were compared, conventional mode (CONV), X2 mashed mode (X2: two adjacent projection angles are added together), and X4 mashed mode (X4: four adjacent angles added). A point source of (18)F was used to measure spatial resolution. A hot spot phantom made of 6 hot spheres (10-38 mm in diameter) within water of 20 cm in diameter was scanned to evaluate the recovery coefficient (RC). A lung-heart-liver phantom made of homogeneous radioactive myocardium, a spherical hot mass in the lung (10 mm in diameter), and background activity in the liver was scanned to evaluate the homogeneity of the myocardial wall. The quality of the reconstructed images was evaluated in terms of the normalized mean square error (NMSE), Bull's eye map, profile curve, and peak value of the spherical hot mass. The reconstruction times of X2 and X4 were one-half and one-quarter, respectively, of that of CONV. In terms of spatial resolution, FWHM of CONV, X2, and X4 were, 4.26, 4.33, and 4.48 (mm) at the center, 4.81, 5.68, and 8.73 tangentially, and 8.01, 8.19, and 8.27 radially at R=200 mm, respectively. RC was similar for all methods. The NMSE values of X2 and X4 compared with CONV were 0.0003 and 0.0014, respectively. In the hot mass, these methods showed almost the same profile curves, although the peak value of X4 was only -1.95% less than that of CONV. Although the result of spatial resolution of X4 was slightly degraded, image quality and physical performance were good. Therefore, the X4 mashed mode used with angular compression was considered clinically useful.     

Optimization of contrast dosage for gadobenate dimeglumine-enhanced high-resolution whole-body 3D magnetic resonance angiography

RATIONALE AND OBJECTIVES: To determine the optimal dose of gadobenate dimeglumine for diagnostic high-resolution whole-body 3D-MR angiography. METHODS: Ten healthy volunteers were examined three times with an ascending dose of Gd-BOPTA (0.1/0.2/0.3 mmol/kg BW). Three-dimensional data sets were collected with a rolling table platform (AngioSURF; MR-Innovation GmbH, Essen, Germany) which integrates the torso surface coil, using a 3D FLASH sequence at five stations from carotid arteries to the trifurcation vessels in 72 seconds. SNR- and contrast-to-noise-values were calculated for 30 segments per patient. For qualitative evaluation a 4-point-visualization scale was used. RESULTS: Overall, significantly (P < 0.05) higher signal-to-noise values and CNR values were determined for Gd-BOPTA at a dose of 0.2 and 0.3 mmol/kg compared with 0.1 mmol/kg. Similarly, the qualitative analysis demonstrated image quality to be superior with 0.2 and 0.3 mmol/kg compared with 0.1 mmol/kg (P < 0.05). Qualitative and quantitative assessment failed to demonstrate a statistically significant difference between 0.2 and 0.3 mmol/kg BW (P > 0.05). CONCLUSION: A dose of 0.2 mmol/kg BW Gd-BOPTA rendered diagnostic image quality in all vascular segments of all volunteers.